News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,005 Results
Type
Article (8050)
Company Profile (141)
Press Release (477909)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166753)
Career Advice (305)
Deals (25740)
Drug Delivery (7)
Drug Development (52884)
Employer Resources (14)
FDA (9761)
Job Trends (8574)
News (238204)
Policy (17907)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (490)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33154)
ALS (108)
Alzheimer's disease (985)
Antibody-drug conjugate (ADC) (283)
Approvals (10408)
Artificial intelligence (333)
ASCO (159)
Autoimmune disease (220)
Automation (29)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6958)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (1)
Bladder cancer (139)
Brain cancer (31)
Breast cancer (518)
Cancer (3757)
Cardiovascular disease (226)
Career advice (245)
Career pathing (1)
CAR-T (178)
CDC (1)
CDMO (15)
Celiac Disease (1)
Cell therapy (486)
Cervical cancer (35)
Clinical research (48044)
Collaboration (1279)
Commercialization (3)
Compensation (1532)
Complete response letters (34)
COVID-19 (763)
CRISPR (64)
C-suite (804)
Cystic fibrosis (87)
Data (5847)
Denatured (4)
Depression (106)
Dermatology (67)
Diabetes (354)
Diagnostics (4219)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (158)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73747)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88110)
Executive appointments (714)
FDA (12489)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (945)
Gene editing (126)
Generative AI (11)
Gene therapy (333)
GLP-1 (294)
Government (949)
Grass and pollen (2)
Guidances (281)
Healthcare (9368)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (68)
Immunology and inflammation (106)
Immuno-oncology (61)
Indications (162)
Infectious disease (955)
Inflammatory bowel disease (128)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (261)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (18)
Liver cancer (45)
Longevity (19)
Lung cancer (541)
Lymphoma (257)
Machine learning (29)
Management (3)
Manufacturing (565)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8678)
Medtech (8837)
Mergers & acquisitions (14411)
Metabolic disorders (726)
mRNA (62)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (227)
Neuropsychiatric disorders (40)
Neuroscience (1869)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (231)
Opinion (10)
Ovarian cancer (161)
Pain (177)
Pancreatic cancer (206)
Parkinson's disease (206)
Partnered (12)
Patents (497)
Patient recruitment (530)
Patient selection (2)
Peanut (32)
People (41364)
Peptides (2)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15520)
Phase 2 (21456)
Phase 3 (14468)
Pipeline (7685)
Policy (18)
Postmarket research (1570)
Preclinical (6554)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (195)
Rare diseases (588)
Real estate (3022)
Recruiting (6)
Regenerative medicine (2)
Regulatory (14952)
Reports (23)
Research institute (585)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (102)
Series A (163)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Supply chain (51)
Vaccines (334)
Venture capital (17)
Weight loss (75)
Women's health (88)
Date
Today (49)
Last 7 days (281)
Last 30 days (1416)
Last 365 days (19056)
2026 (13613)
2025 (19254)
2024 (22986)
2023 (26541)
2022 (34587)
2021 (37180)
2020 (33480)
2019 (23262)
2018 (17496)
2017 (18769)
2016 (17922)
2015 (24263)
2014 (21683)
2013 (18135)
2012 (20222)
2011 (20441)
2010 (20332)
Location
Africa (229)
Alabama (77)
Alaska (2)
Arizona (310)
Arkansas (11)
Asia (17961)
Australia (2108)
California (12348)
Canada (3233)
China (544)
Colorado (496)
Connecticut (427)
Delaware (214)
Europe (24704)
Florida (1853)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (727)
India (52)
Indiana (323)
Iowa (16)
Japan (422)
Kansas (103)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1231)
Massachusetts (8100)
Michigan (314)
Minnesota (572)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (122)
New Hampshire (60)
New Jersey (2691)
New Mexico (12)
New York (2896)
North Carolina (1316)
North Dakota (4)
Northern California (6211)
Ohio (293)
Oklahoma (14)
Oregon (18)
Pennsylvania (2295)
Puerto Rico (21)
Rhode Island (30)
South America (406)
South Carolina (78)
South Dakota (1)
Southern California (5137)
Tennessee (125)
Texas (2003)
United States (40021)
Utah (372)
Vermont (1)
Virginia (160)
Washington D.C. (38)
Washington State (955)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
486,005 Results for "glycomimetics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
June 6, 2025
·
10 min read
BioCapital
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET.
April 25, 2024
·
1 min read
Press Releases
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
June 16, 2025
·
7 min read
Press Releases
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma
October 29, 2024
·
15 min read
Business
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023.
March 27, 2024
·
9 min read
BioCapital
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET.
February 26, 2024
·
1 min read
BioCapital
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET.
March 13, 2024
·
1 min read
Drug Development
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced comprehensive results from the company’s pivotal Phase 3 study of uproleselan in R/R AML.
June 4, 2024
·
9 min read
Drug Development
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
GlycoMimetics, Inc., a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML.
May 6, 2024
·
6 min read
BioCapital
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET.
November 9, 2023
·
1 min read
1 of 48,601
Next
